Related Experiment Video
Updated: Apr 20, 2026
06:17
A11-positive β-amyloid Oligomer Preparation and Assessment Using Dot Blotting Analysis
Published on: May 22, 2018
12.8K
Exploring the Hydrazone Group in Multifunctional Approaches for Alzheimer's Disease Therapy
Carola Grondona1, Eleonora Russo1, Bruno Tasso1
1Department of Pharmacy, University of Genoa, Genoa, Italy.
Chemmedchem
|April 19, 2026
Summary
Hydrazone compounds show promise for Alzheimer's disease (AD) therapy by targeting multiple pathological pathways. This review highlights their potential to combat the complex, multifactorial nature of AD, offering new therapeutic avenues.
Area of Science:
- Medicinal Chemistry
- Neuroscience
- Pharmacology
Background:
- Alzheimer's disease (AD) is a complex neurodegenerative disorder with multiple pathological processes.
- Current single-target therapies offer limited symptomatic relief, necessitating novel approaches for disease modification.
- Hydrazones are versatile chemical scaffolds with potential for multitarget drug design.
Purpose of the Study:
- To provide a comprehensive overview of hydrazone-containing compounds for AD therapy.
- To highlight the activity of hydrazones against classical and emerging AD targets.
- To analyze structure-activity relationships and design strategies for hydrazone-based multitarget-directed ligands (MTDLs).
Main Methods:
- Literature review of hydrazone compounds reported between 2020-2025.
- Analysis of their activity on key enzymes and pathological mechanisms in AD.
- Evaluation of multitarget profiles and structure-activity relationships (SARs).
Main Results:
- Hydrazone-based MTDLs demonstrate efficacy against multiple AD-related targets, including cholinesterases (ChEs), carbonic anhydrase, BACE1, and α-glycosidase.
- These compounds exhibit potential for addressing the multifactorial nature of AD.
- Rational design strategies are being employed to optimize hydrazone scaffolds for AD treatment.
Conclusions:
- Hydrazone-based MTDLs represent a promising strategy for developing effective Alzheimer's disease therapies.
- Their ability to modulate multiple pathogenic pathways offers a significant advantage over single-target approaches.
- Further research into hydrazone chemistry holds potential for advancing AD treatment.
More Related Videos
Related Concept Videos
01:22Alzheimer's Disease: Treatment
1.3K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.3K
01:26Alzheimer's Disease: Overview
2.0K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
2.0K
01:22Dementia l: Introduction
3
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
3
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
926
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
926
01:23Alzheimer Disease ll: Pathophysiology
2
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and...
2
01:29Alzheimer Disease l: Introduction
4
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
4